Analysts Offer Insights on Healthcare Companies: FibroGen (FGEN), Karyopharm Therapeutics (KPTI) and Day One Biopharmaceuticals (DAWN)
TipRanksFeb 27 11:30
Sell Rating on FibroGen Amid Skepticism Over Clinical Outcomes and Drug Efficacy
TipRanksFeb 14 11:45
Analysts Offer Insights on Healthcare Companies: FibroGen (FGEN), BioNTech SE (BNTX) and Sensei Biotherapeutics (SNSE)
TipRanksNov 7, 2023 11:50
BofA Downgrades FibroGen to Underperform, Cites Unfavorable Catalysts
Seeking AlphaAug 9, 2023 04:29
B of A Securities Downgrades FibroGen to Underperform, Lowers Price Target to $2
BenzingaAug 8, 2023 20:49
FibroGen Analyst Ratings
BenzingaAug 8, 2023 20:48
BofA Securities Downgrades FibroGen to Neutral From Buy, Lowers Price Target to $4 From $29
MT NewswiresJun 27, 2023 22:03
Goldman Sachs Adjusts FibroGen's Price Target to $2 From $16, Keeps Sell Rating
MT NewswiresJun 27, 2023 20:37
Analysts Have Conflicting Sentiments on These Healthcare Companies: MoonLake Immunotherapeutics (MLTX), Option Care Health (OPCH) and FibroGen (FGEN)
TipRanksJun 27, 2023 07:10
FibroGen (FGEN) Receives a Sell From Goldman Sachs
TipRanksJun 27, 2023 03:05
Stifel Downgrades FibroGen to Hold From Buy, Cuts Price Target to $11 From $28
MT NewswiresJun 27, 2023 01:28
FibroGen (FGEN) Receives a Sell From Goldman Sachs
TipRanksJun 7, 2023 22:25
Analysts' Opinions Are Mixed on These Healthcare Stocks: Tonix Pharma (TNXP), ANI Pharmaceuticals (ANIP) and FibroGen (FGEN)
TipRanksMay 9, 2023 20:36
Goldman Sachs Remains a Sell on FibroGen (FGEN)
TipRanksMay 6, 2023 02:55
Goldman Sachs Sticks to Their Sell Rating for FibroGen (FGEN)
TipRanksMay 2, 2023 12:15
Cowen Adjusts Price Target on FibroGen to $25 From $15, Maintains Market Perform Rating
MT NewswiresFeb 28, 2023 21:43
Cowen & Co. Maintains Market Perform on FibroGen, Raises Price Target to $25
BenzingaFeb 28, 2023 21:15
Analysts Offer Insights on Healthcare Companies: Perrigo Company (PRGO), FibroGen (FGEN) and Disc Medicine (IRON)
TipRanksFeb 28, 2023 19:46
Goldman Sachs Maintains Sell on FibroGen, Raises Price Target to $16
BenzingaFeb 23, 2023 20:50
Goldman Sachs Increases Price Target on FibroGen to $16 From $9, Maintains Sell Rating
MT NewswiresFeb 22, 2023 00:03
No Data
No Data